Na Uy -
Tiếng Na Uy -
Statens legemiddelverk
cozaar 2.5 mg/ ml
merck sharp & dohme b.v. - losartankalium - pulver og væske til mikstur, suspensjon - 2.5 mg/ ml
Na Uy -
Tiếng Na Uy -
Statens legemiddelverk
cozaar 12.5 mg
merck sharp & dohme b.v. - losartankalium - tablett, filmdrasjert - 12.5 mg
Na Uy -
Tiếng Na Uy -
Statens legemiddelverk
cozaar 50 mg
farmagon - losartankalium - tablett, filmdrasjert - 50 mg
Na Uy -
Tiếng Na Uy -
Statens legemiddelverk
cozaar 50 mg
farmagon - losartankalium - tablett, filmdrasjert - 50 mg
Liên Minh Châu Âu -
Tiếng Na Uy -
EMA (European Medicines Agency)
ulipristal acetate gedeon richter
gedeon richter plc. - ulipristalacetat - leiomyomer - sex hormoner og modulatorer av genital systemet, - ulipristal acetat er indikert for en behandling løpet av pre-operativ behandling av moderate til alvorlige symptomer på livmor fibroids i voksne kvinner i reproduktiv alder. ulipristal acetat er indikert for intermitterende behandling av moderate til alvorlige symptomer på livmor fibroids i voksne kvinner i reproduktiv alder som ikke er kvalifisert for kirurgi.
Liên Minh Châu Âu -
Tiếng Na Uy -
EMA (European Medicines Agency)
silodosin recordati
recordati ireland ltd - silodosin - prostatisk hyperplasi - urologicals, alfa-antagonister adrenoreceptor - behandling av tegn og symptomer på godartet prostatahyperplasi (bph) hos voksne menn.
Liên Minh Châu Âu -
Tiếng Na Uy -
EMA (European Medicines Agency)
ultomiris
alexion europe sas - ravulizumab - hemoglobinuri, paroksysmal - selektive immunosuppressiva - paroxysmal nocturnal haemoglobinuria (pnh)ultomiris is indicated in the treatment of adult and paediatric patients with a body weight of 10 kg or above with pnh:- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months (see section 5. atypical haemolytic uremic syndrome (ahus)ultomiris is indicated in the treatment of patients with a body weight of 10 kg or above with ahus who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab (see section 5. generalized myasthenia gravis (gmg)ultomiris is indicated as an add-on to standard therapy for the treatment of adult patients with gmg who are anti-acetylcholine receptor (achr) antibody-positive. neuromyelitis optica spectrum disorder (nmosd)ultomiris is indicated in the treatment of adult patients with nmosd who are anti-aquaporin 4 (aqp4) antibody-positive (see section 5. ultomiris is indicated in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (pnh):- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months. ultomiris is indicated in the treatment of adult patients with atypical haemolytic uremic syndrome (ahus) who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab.
Liên Minh Châu Âu -
Tiếng Na Uy -
EMA (European Medicines Agency)
ayvakyt
blueprint medicines (netherlands) b.v. - avapritinib - gastrointestinal stromal tumors - andre cytostatika, protein kinase hemmere - ayvakyt is indicated as monotherapy for the treatment of adult patients with unresectable or metastatic gastrointestinal stromal tumours (gist) harbouring the platelet-derived growth factor receptor alpha (pdgfra) d842v mutation.
Liên Minh Châu Âu -
Tiếng Na Uy -
EMA (European Medicines Agency)
rozlytrek
roche registration gmbh - entrectinib - cancer; carcinoma, non-small-cell lung - antineoplastiske midler - rozlytrek as monotherapy is indicated for the treatment of adult and paediatric patients 12 years of age and older with solid tumours expressing a neurotrophic tyrosine receptor kinase (ntrk) gene fusion,who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, andwho have not received a prior ntrk inhibitorwho have no satisfactory treatment options. rozlytrek as monotherapy is indicated for the treatment of adult patients with ros1 positive, advanced non small cell lung cancer (nsclc) not previously treated with ros1 inhibitors.